Esperion (ESPR) announced that Otsuka Pharmaceutical, the Company’s partner for the development and commercialization of NEXLETO: tablets in Japan, has received approval from the Japanese Ministry of Health, Labour and Welfare to market NEXLETOL as a treatment for hypercholesterolemia and familial hypercholesterolemia. Under the terms of the collaboration and license agreement, Esperion is eligible to receive significant milestone payments upon regulatory approval and National Health Insurance Price Listing for NEXLETOL in the Otsuka territory. In addition, Esperion is eligible to receive additional sales milestone payments based on total net sales achievements by Otsuka in Japan, as well as tiered royalties ranging from fifteen percent to thirty percent on net sales in Japan.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion bempedoic acid receives level 1a recommendation in ESC/EAS guidelines
- Esperion Delays Q2 2025 Financial Report Filing
- Esperion Therapeutics Reports Strong Q2 2025 Growth
- Esperion Therapeutics’ Earnings Call Highlights Growth
- Esperion’s Strong Financial Performance and Strategic Initiatives Drive Buy Rating